Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) was the target of a large decline in short interest in July. As of July 15th, there was short interest totaling 6,859 shares, a decline of 33.8% from the June 30th total of 10,359 shares. Based on an average daily trading volume, of 6,436 shares, the short-interest ratio is presently 1.1 days.
Defence Therapeutics Price Performance
Shares of OTCMKTS:DTCFF opened at $0.30 on Friday. The company’s fifty day moving average price is $0.34 and its 200-day moving average price is $0.39. Defence Therapeutics has a one year low of $0.25 and a one year high of $0.78.
About Defence Therapeutics
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
See Also
- Five stocks we like better than Defence Therapeutics
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
